Skip to main content
Fig. 4 | Lipids in Health and Disease

Fig. 4

From: Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non–small-cell lung cancer

Fig. 4

Lipid identification in advanced NSCLC patients in the PD group. After the administering anlotinib along with PD-1/PD-L1 inhibitor, the analysis of lipid volume in various lipid categories was conducted on the samples collected from the PR group. Significant variations in relation to the pre-treatment patient lipid levels were determined using Student’s t-test. Asterisks indicate the presence of such significant differences when P -value was lower than 0.05

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X